Cart
sales@molnova.com
PUMA BH3 (TFA)
CAS No. ——
PUMA BH3 (TFA)( —— )
Catalog No. M30410 CAS No. ——
PUMA BH3 (TFA) is a p53 upregulated modulator of apoptosis (PUMA) BH3 domain peptide, acts as a direct activator of Bak, with a Kd of 26 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePUMA BH3 (TFA)
-
NoteResearch use only, not for human use.
-
Brief DescriptionPUMA BH3 (TFA) is a p53 upregulated modulator of apoptosis (PUMA) BH3 domain peptide, acts as a direct activator of Bak, with a Kd of 26 nM.
-
DescriptionPUMA BH3 (TFA) is a p53 upregulated modulator of apoptosis (PUMA) BH3 domain peptide, acts as a direct activator of Bak, with a Kd of 26 nM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorBak
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight3163.32
-
Molecular FormulaC130H203F3N42O45S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:Glu-Glu-Gln-Trp-Ala-Arg-Glu-Ile-Gly-Ala-Gln-Leu-Arg-Arg-Met-Ala-Asp-Asp-Leu-Asn-Ala-Gln-Tyr-Glu-Arg
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Dai H, et al. Evaluation of the BH3-only protein Puma as a direct Bak activator. J Biol Chem. 2014 Jan 3;289(1):89-99.
molnova catalog
related products
-
Lastourvilline
Lastourvilline
-
MYF-01-37
MYF-01-37 is a novel covalent TEAD inhibitor.
-
(R)-Omeprazole Sodiu...
(R)-Omeprazole (sodium) (Standard) is the analytical standard of (R)-Omeprazole (sodium). This product is intended for research and analytical applications. (R)-Omeprazole sodium is a gastric acid resistant compound with activity to inhibit gastric acid secretion. (R)-Omeprazole sodium is metabolized in vivo, and its metabolism is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. (R)-Omeprazole sodium exhibits reversible direct and metabolism-dependent inhibition of CYP2C19.
